Menstrual discomfort, changes in ovarian reserve, and fatigue after childbirth raise different questions at different stages of a woman's life. Understanding the research behind a supplement helps you decide which information is relevant to your own circumstances.
L-Ergothioneine is a naturally occurring dietary antioxidant found in mushrooms and other foods. GeneIII®'s human research includes studies of menstrual symptoms, ovarian reserve markers, and postpartum well-being. This guide explains the participants, findings, and practical meaning of those studies, alongside research conducted outside GeneIII.
Key Takeaways
- GeneIII has completed three women's health studies, covering primary dysmenorrhea, ovarian reserve, and postpartum well-being, each using 120 mg/day in its research protocol.
- The menstrual discomfort study was randomized, double-blind, and placebo-controlled. Mean peak-pain scores fell from 4.80 to 2.32 in the ergothioneine group, compared with 4.10 to 3.45 with placebo.
- The ovarian reserve study is published in BMC Women's Health. Among 36 completers, mean AMH rose from 1.81 to 2.46 ng/mL, about 35.9% above baseline.
- The postpartum trial was randomized and placebo-controlled and enrolled women who had stopped breastfeeding.
- Study doses and timelines describe research protocols, not a personalized recommendation or a set time to results.
Why L-Ergothioneine Matters for Women
Humans obtain ergothioneine from the diet rather than producing it themselves. Its scientific interest also comes from a highly selective transporter, commonly called OCTN1 or ETT, which helps certain cells take up ergothioneine. A 2005 study in PNAS identified this transporter and its uptake mechanism.
In 2018, biochemist Bruce Ames listed ergothioneine among candidate "longevity vitamins" in a PNAS article, providing a theoretical perspective for its study in healthy aging.
This cellular background is a useful starting point for understanding antioxidant research. For women considering a supplement, the next question is what human studies have measured.
GeneIII's Three Women's Health Studies
| Research focus | Participants and design | Research regimen | Registration and source |
|---|---|---|---|
| Primary dysmenorrhea | 40 women; randomized, double-blind, placebo-controlled | 120 mg/day for three menstrual cycles | ChiCTR2500112557; preprint (July 18, 2026 version) |
| Ovarian reserve | 40 enrolled, 36 completed; open-label, self-controlled pilot | 120 mg/day for three menstrual cycles | ChiCTR2500104484; peer-reviewed article, BMC Women's Health |
| Postpartum well-being | 40 women who had stopped breastfeeding; randomized, double-blind, placebo-controlled | 120 mg/day for 30 days | ChiCTR2500114171; preprint |
Period Pain: What the Placebo-Controlled Study Found
Primary dysmenorrhea can interrupt work, study, and daily activities. GeneIII's study investigated this specific condition in women with primary dysmenorrhea.
Over three cycles, mean peak-pain VAS scores fell from 4.80 to 2.32 in the ergothioneine group and from 4.10 to 3.45 in the placebo group. The preprint reports a significant difference between groups at the third cycle, and also assessed menstrual symptom scores. Read the study.
Researchers measured symptoms against a comparison group, not only before and after supplementation. The study was also covered by New Scientist. As a small trial, it provides encouraging early evidence. New, severe, or worsening menstrual pain warrants medical assessment.
Ovarian Health: Understanding the Hormone Markers
Ovarian reserve research examines markers associated with the remaining follicle pool. One commonly used marker is anti-Müllerian hormone, or AMH. A marker helps describe ovarian status, but it is not the same as an individual's likelihood of pregnancy.
GeneIII's pilot enrolled women aged 35–45 with suboptimal ovarian function. Among 36 completers, mean AMH increased from 1.81 to 2.46 ng/mL (p = 0.018), about 35.9% above baseline. The article also reports changes in FSH and estradiol, alongside symptom questionnaires. The results are published in BMC Women's Health.
This pilot recorded changes in ovarian reserve-related markers during supplementation and provides a basis for further controlled research. It used a self-controlled before-and-after design and did not assess pregnancy or live-birth outcomes.
Postpartum Recovery: Quality of Life, Fatigue, and Sleep
Recovery after childbirth involves more than one symptom. GeneIII's postpartum study therefore assessed quality of life, fatigue, and sleep separately.
This 30-day randomized, double-blind, placebo-controlled study enrolled 40 women within 24 months of childbirth who had completely stopped breastfeeding. It used the SF-36 quality-of-life questionnaire, the FS-14 fatigue scale, and the PSQI sleep quality index to assess changes during supplementation. The study extends GeneIII's research into postpartum quality of life, fatigue, and sleep in women who were not breastfeeding. Read the preprint.
Skin: Research Beyond GeneIII
Two external studies illustrate research on oral ergothioneine and skin. Neither is a GeneIII trial.
- Ergothioneine capsules, 8 weeks: a preprint reports skin measurements in 66 women who completed the study, including pigmentation, redness, elasticity, and wrinkles. The tested dose was 30 mg/day. Read the preprint.
- Ergothioneine-rich mushroom tablets, 12 weeks: a trial randomized 80 women to tablets supplying 25 mg/day of ergothioneine or placebo, measuring moisture, transepidermal water loss, and facial characteristics. The report found a hydration benefit at week eight. Published trial.
These studies broaden the discussion of oral ergothioneine and skin, and each should be read with its own formulation, outcomes, and publication status.
Sleep: A Specific Observation in the Liver Study
GeneIII's liver-related study (ChiCTR2400093739) also assessed sleep-related questionnaire components. After 30 days at 60 mg/day, the PSQI daytime dysfunction component decreased by 51.56% from baseline (p = 0.0038). This concerns daytime functioning, not total sleep quality. The study was open-label and self-controlled. Study report.
Separate research has examined sleep directly: a four-week study using 20 mg/day was published in 2022 in the Journal of Functional Foods. GeneIII's sleep research guide explains these studies in more detail.
Cognition: An Active Research Direction
GeneIII has registered a cognition study, ChiCTR2500112606, involving adults with mild cognitive impairment. Its current status can be checked in the registry.
Outside GeneIII, a 147-participant trial studied 10 or 25 mg/day over 16 weeks. Its primary composite-memory outcome did not show a significant treatment effect, while selected subjective memory and sleep measures showed positive findings. Read the trial.
Energy and Longevity: How Ergothioneine Relates to NMN
NMN and ergothioneine attract scientific interest for different reasons. NMN is a precursor involved in NAD+ metabolism, which supports cellular energy production. Ergothioneine is studied for its antioxidant chemistry and its selective uptake into cells through a dedicated transporter. The two act at different points in cellular health research, and neither replaces the other.
Multi-ingredient formulas combining ergothioneine with other compounds, such as PQQ and NR, have also been studied. Results from such formulas reflect the full combination tested, so each formula is best understood by its actual ingredients and human evidence. Research on a formula containing ergothioneine, PQQ and NR.
A Shared Cellular Foundation Across Women's Health
Oxidative processes and cellular function are relevant to many biological systems. This gives a scientific basis for investigating ergothioneine across different areas of women's health, with each outcome supported by its own study.
GeneIII connects this scientific interest with identifiable human studies in menstrual discomfort, ovarian reserve, and postpartum well-being. The clearest way to explore the program is through the study designs, measured outcomes, and original reports.
Usage Guide
- Dose: the three women's health protocols used 120 mg/day. This is a study dose, not a general recommendation. Refer to the current GeneIII product label.
- Duration: the studies ran for 30 days or three menstrual cycles. These are observation periods, not set times to benefit.
- Personal relevance: participants met specific entry criteria, so matching an age group alone does not establish suitability.
- Safety: discuss use with a qualified healthcare professional if you are pregnant, breastfeeding, planning pregnancy, taking medication, or managing a health condition. Stop use and seek advice if you experience discomfort.
Why Consider GeneIII?
GeneIII produces L-Ergothioneine through its in-house fermentation process and supports its quality information with third-party testing. A tested GeneIII raw-material sample showed purity above 99.99% by HPLC peak-area normalization. GeneIII L-Ergothioneine has received an FDA 'No Questions' Letter for its GRAS notification (GRN 001270), concerning the ingredient's specified intended food uses. GeneIII's quality and safety guide and clinical research overview explain the testing records and human studies in more detail.
For current ingredients, capsule specifications, and directions, visit GeneIII® L-Ergothioneine 30mg.
FAQ About L-Ergothioneine for Women's Health
Q1: Which Groups of Women Were Included in GeneIII's Studies?
Women with primary dysmenorrhea, women aged 35–45 with suboptimal ovarian function, and women within 24 months of childbirth who had stopped breastfeeding. The findings relate to these study populations.
Q2: How Long Did the Women's Health Studies Last?
The menstrual and ovarian studies ran for three menstrual cycles, and the postpartum study for 30 days. These are study observation periods and do not predict when an individual will notice a change.
Q3: What Dose Was Used, and Is It the Recommended Serving?
All three studies used 120 mg/day under a research protocol. This is not the product's recommended serving; follow the current product label and professional guidance.
Q4: Is L-Ergothioneine a Hormone?
No. L-Ergothioneine is a dietary antioxidant compound. The ovarian reserve study measured hormone-related markers such as AMH as research outcomes.
Q5: Was Supplementation Continued During Menstruation in the Studies?
Yes. The menstrual and ovarian studies used continuous supplementation across three cycles. This describes the study protocol; individual use should follow the product label.
Q6: Can L-Ergothioneine Be Used When Planning Pregnancy or Breastfeeding?
Consult a qualified healthcare professional first. The postpartum study enrolled only women who had stopped breastfeeding, and the ovarian reserve study did not assess pregnancy outcomes.
Q7: How Can the Studies Be Verified?
Use the report links in this article, or search the registration numbers in ChiCTR or the WHO ICTRP.
References
- Gründemann D, et al. Discovery of the ergothioneine transporter. PNAS, 2005.
- Ames BN. Prolonging healthy aging: Longevity vitamins and proteins. PNAS, 2018.
- GeneIII primary dysmenorrhea study, preprint (July 18, 2026 version)
- Ovarian reserve pilot, BMC Women's Health
- Postpartum trial, preprint
- GeneIII liver study, preprint
- Oral ergothioneine capsules and skin, 8-week study, medRxiv preprint
- Ergothioneine-rich mushroom tablets and skin, 12-week trial
- Ergothioneine and sleep, Journal of Functional Foods, 2022
- Formula containing ergothioneine, PQQ and NR, Current Developments in Nutrition, 2025
- 147-participant cognition, memory, and sleep trial
- New Scientist coverage of the menstrual discomfort study
Related Reading
- L-Ergothioneine and menstrual discomfort
- A women's guide to ovarian health
- L-Ergothioneine and postpartum recovery
- Ergothioneine Brands Backed by Human Clinical Studies
*Disclaimer
This content is for informational purposes only and does not constitute medical advice. The studies discussed use different designs, including randomized, placebo-controlled trials and open-label, self-controlled studies. Findings should be interpreted in the context of each study’s participants, methods, and publication status. If you are pregnant, breastfeeding, planning pregnancy, taking medication, or managing a medical condition, consult a qualified healthcare professional before use.
